ID   Evsa-T
AC   CVCL_1207
SY   EVSA-T; EVSa-T; EVSA/T; Evsa T; EVSAT; EvsaT
DR   CLO; CLO_0002955
DR   EFO; EFO_0006574
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 885
DR   BioSample; SAMN03472910
DR   BioSample; SAMN03473598
DR   BioSample; SAMN10988228
DR   cancercelllines; CVCL_1207
DR   Cell_Model_Passport; SIDM01042
DR   ChEMBL-Cells; CHEMBL3307361
DR   ChEMBL-Targets; CHEMBL614295
DR   Cosmic; 906862
DR   Cosmic; 944298
DR   Cosmic; 997931
DR   Cosmic; 1046926
DR   Cosmic; 1287906
DR   Cosmic; 1289388
DR   Cosmic; 2165020
DR   Cosmic; 2750518
DR   Cosmic; 2787554
DR   Cosmic-CLP; 906862
DR   DepMap; ACH-001065
DR   DSMZ; ACC-433
DR   DSMZCellDive; ACC-433
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 906862
DR   GEO; GSM274650
DR   GEO; GSM344366
DR   GEO; GSM344416
DR   GEO; GSM421866
DR   GEO; GSM783964
DR   GEO; GSM843500
DR   GEO; GSM843501
DR   GEO; GSM847317
DR   GEO; GSM847471
DR   GEO; GSM1172953
DR   GEO; GSM1374477
DR   GEO; GSM1661978
DR   GEO; GSM1669780
DR   IARC_TP53; 24357
DR   LINCS_LDP; LCL-1313
DR   PharmacoDB; EVSAT_349_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1207
DR   PubChem_Cell_line; CVCL_1207
DR   TOKU-E; 4049
DR   Wikidata; Q54832986
RX   PubMed=212193;
RX   PubMed=1000504;
RX   PubMed=1000505;
RX   PubMed=3702420;
RX   PubMed=9488600;
RX   PubMed=9570382;
RX   PubMed=16142302;
RX   PubMed=16397213;
RX   PubMed=16541312;
RX   PubMed=19593635;
RX   PubMed=20164919;
RX   PubMed=23601657;
RX   PubMed=24176112;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26759240;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=35839778;
WW   https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: GrayJW breast cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: 25 hours (PubMed=9488600); ~50 hours (DSMZ=ACC-433).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; c.687+1_687+2delGT; ClinVar=VCV000483268; Zygosity=Homozygous (PubMed=19593635).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.951_954delACTT) (p.VL317fs) (V317fs*3); Zygosity=Homozygous (PubMed=19593635).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Cys (c.722C>G); ClinVar=VCV000177791; Zygosity=Homozygous (PubMed=16541312; Cosmic-CLP).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.86%; Native American=1.1%; East Asian, North=2.9%; East Asian, South=0%; South Asian=8.5%; European, North=19.45%; European, South=67.19% (PubMed=30894373).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): Cosmic-CLP; DSMZ; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11,12 (Cosmic-CLP; DSMZ)
ST   D13S317: 12 (PubMed=25877200)
ST   D16S539: 9
ST   D18S51: 12,17
ST   D19S433: 13
ST   D21S11: 30,31.2
ST   D2S1338: 24
ST   D3S1358: 14,17
ST   D5S818: 12,13
ST   D7S820: 10,12
ST   D8S1179: 16
ST   FGA: 21,24,25
ST   Penta D: 12,14
ST   Penta E: 12,16
ST   TH01: 6
ST   TPOX: 8
ST   vWA: 15,16
DI   NCIt; C4872; Breast carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_5G37 ! Evsa-E
SX   Female
AG   58Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 41
//
RX   PubMed=212193;
RA   Engel L.W., Young N.A.;
RT   "Human breast carcinoma cells in continuous culture: a review.";
RL   Cancer Res. 38:4327-4339(1978).
//
RX   PubMed=1000504;
RA   Lippman M.E., Bolan G., Huff K.;
RT   "The effects of estrogens and antiestrogens on hormone-responsive
RT   human breast cancer in long-term tissue culture.";
RL   Cancer Res. 36:4595-4601(1976).
//
RX   PubMed=1000505;
RA   Lippman M.E., Bolan G., Huff K.;
RT   "The effects of glucocorticoids and progesterone on hormone-responsive
RT   human breast cancer in long-term tissue culture.";
RL   Cancer Res. 36:4602-4609(1976).
//
RX   PubMed=3702420; DOI=10.1016/0022-4731(86)90083-X;
RA   Devleeschouwer N., Olea-Serrano N., Leclercq G., Legros N.,
RA   Heuson J.-C.;
RT   "Induction of progesterone receptor in an estrogen, progesterone
RT   receptor-negative breast cancer cell line.";
RL   J. Steroid Biochem. 24:365-368(1986).
//
RX   PubMed=9488600; DOI=10.1007/s002800050744;
RA   Ma J.-G., Maliepaard M., Nooter K., Boersma A.W.M., Verweij J., Stoter G.,
RA   Schellens J.H.M.;
RT   "Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a
RT   panel of eight solid-tumor cell lines in vitro.";
RL   Cancer Chemother. Pharmacol. 41:307-316(1998).
//
RX   PubMed=9570382; DOI=10.1016/S0304-3835(97)00285-1;
RA   Borras M., Lacroix M., Legros N., Leclercq G.;
RT   "Estrogen receptor-negative/progesterone receptor-positive Evsa-T
RT   mammary tumor cells: a model for assessing the biological property of
RT   this peculiar phenotype of breast cancers.";
RL   Cancer Lett. 120:23-30(1997).
//
RX   PubMed=16142302; DOI=10.3892/ijo.27.4.881;
RA   de Longueville F., Lacroix M., Barbuto A.-M., Bertholet V., Gallo D.,
RA   Larsimont D., Marcq L., Zammatteo N., Boffe S., Leclercq G.,
RA   Remacle J.;
RT   "Molecular characterization of breast cancer cell lines by a
RT   low-density microarray.";
RL   Int. J. Oncol. 27:881-892(2005).
//
RX   PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853;
RA   Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M.,
RA   van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.;
RT   "BRCA1 mutation analysis of 41 human breast cancer cell lines reveals
RT   three new deleterious mutants.";
RL   Cancer Res. 66:41-45(2006).
//
RX   PubMed=16541312; DOI=10.1007/s10549-006-9186-z;
RA   Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.;
RT   "Thirteen new p53 gene mutants identified among 41 human breast cancer
RT   cell lines.";
RL   Breast Cancer Res. Treat. 99:97-101(2006).
//
RX   PubMed=19593635; DOI=10.1007/s10549-009-0460-8;
RA   Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F.,
RA   Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J.,
RA   Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M.,
RA   Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M.,
RA   Dinjens W.N.M., Ethier S.P., Clevers H.C., Jochemsen A.G.,
RA   den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.;
RT   "Distinct gene mutation profiles among luminal-type and basal-type
RT   breast cancer cell lines.";
RL   Breast Cancer Res. Treat. 121:53-64(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=23601657; DOI=10.1186/bcr3415;
RA   Riaz M., van Jaarsveld M.T.M., Hollestelle A.,
RA   Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.-J.,
RA   Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A.,
RA   Martens J.W.M.;
RT   "miRNA expression profiling of 51 human breast cancer cell lines
RT   reveals subtype and driver mutation-specific miRNAs.";
RL   Breast Cancer Res. 15:R33.1-R33.17(2013).
//
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26759240; DOI=10.1158/0008-5472.CAN-15-2201;
RA   Nakanishi Y., Walter K., Spoerke J.M., O'Brien C., Huw L.Y.,
RA   Hampton G.M., Lackner M.R.;
RT   "Activating mutations in PIK3CB confer resistance to PI3K inhibition
RT   and define a novel oncogenic role for p110beta.";
RL   Cancer Res. 76:1193-1203(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//